SUPERNUS PHARMACEUTICALS, INC.

Listed Company

SUPNCIK 0001356576NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$718.95M

Net Income

$-38.55M

Total Assets

$1.45B

Equity

$1.06B

Shares Out

58.04M

Op. Cash Flow

$47.33M

SUPN$48.05+42.99% · past yearDBEQ Basic

Daily closing prices

Business

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company developing and commercializing central nervous system (CNS) products including approved treatments for ADHD, Parkinson's disease complications, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company markets its portfolio through dedicated U.S. sales forces targeting specialized healthcare providers, with products distributed primarily through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus operates research and development programs for novel CNS candidates while relying on third-party contract manufacturers for all production; it also holds collaborations with Biogen and Shionogi for zuranolone development and commercialization outside the U.S.

Summary from 10-K filed 2026-03-02

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	719	662	608	667	580
Cost of revenues	75	78	84	87	—
Research and development	106	109	92	75	90
Selling, general and administrative	486	322	336	377	305
Amortization of intangible assets	90	78	82	83	30
Intangible asset impairment charges	0	0	20	0	0
Contingent consideration loss (gain)	25	−6	−2	−510,000	−7
Total costs and expenses	781	580	613	621	494
Operating earnings (loss)	−62	82	−5	46	86
Interest and other income, net	13	16	10	22	−13
Interest expense	0	0	−2	−7	—
Total other income (expense), net	13	16	8	15	—
Earnings (loss) before income taxes	−49	98	3	61	73
Income tax expense (benefit)	−10	24	1	32,000	20
Net earnings (loss)	−39	74	1	61	53
Basic (in dollars per share)	−0.68	1.34	0.02	1.13	1.01
Diluted (in dollars per share)	−0.68	1.32	0.02	1.04	0.98
Basic (in shares)	56	55	55	54	53
Diluted (in shares)	56	56	56	62	54

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	128	69	75	93	203
Marketable securities	180	384	180	—	—
Accounts receivable, net	188	142	144	165	149
Inventories, net	82	54	—	—	—
Prepaid expenses and other current assets	65	36	17	16	27
Total current assets	644	686	493	734	602
Restricted cash	1	0	0	—	—
Property and equipment, net	11	12	14	—	—
Intangible assets, net	569	522	600	702	785
Goodwill	125	117	117	117	118
Deferred income tax assets, net	38	0	—	—	—
Other assets	64	32	38	40	49
Total assets	1,453	1,368	1,278	1,703	1,689
Accounts payable and accrued liabilities	108	76	80	96	118
Accrued product returns and rebates	161	169	154	152	133
Contingent consideration, current portion	31	47	52	21	45
Other current liabilities	38	0	4	17	20
Total current liabilities	338	292	290	688	315
Contingent consideration, long-term	206,000	0	1	34	36
Operating lease liabilities, long-term	30	27	33	36	41
Deferred income tax liabilities, net	0	5	25	50	85
Other liabilities	22	8	6	9	16
Total liabilities	391	332	356	816	873
Commitments and contingencies (Note 18)	—	—	—	—	—
Common stock, $0.001 par value; 130,000,000 shares authorized; 57,457,462 and 55,743,095 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	57,000	56,000	55,000	54,000	53,000
Additional paid-in capital	544	479	439	408	434
Accumulated other comprehensive loss, net of tax	−44,000	−189,000	−593,000	−3	2
Retained earnings	518	556	483	481	380
Total stockholders' equity	1,062	1,036	922	886	816
Total liabilities and stockholders' equity	1,453	1,368	1,278	1,703	1,689

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	92	80	85	86	33
Amortization of deferred financing costs and debt discount	0	0	532,000	2	18
Realized loss (gains) from sales of marketable securities	439,000	−9,000	0	—	—
Amortization of premium/discount on marketable securities	−2	2	−122,000	3	418,000
Share-based compensation expense	33	28	27	18	18
Deferred income tax benefit	5	−20	−26	−26	−5
Inventory valuation write-down	2	9	8	10	—
Payment of contingent consideration	−5	0	0	—	—
Noncash lease expense	8	5	7	—	—
Other noncash adjustments, net	2	2	−606,000	1	−1
Accounts receivable	−22	2	19	−16	4
Inventories	−8	16	6	−18	−15
Prepaid expenses and other assets	−13	−19	−334,000	12	—
Accrued product returns and rebates	−8	14	3	19	5
Accounts payable and other liabilities	−25	−15	−36	−19	18
Net cash provided by operating activities	47	172	111	117	127
Acquisition of Sage, net of cash acquired	−293	0	0	0	−950,000
Purchases of marketable securities	−476	−688	−102	−407	−312
Maturities of marketable securities	774	499	371	191	—
Purchases of property and equipment	−1	−725,000	−551,000	−412,000	—
Net cash provided by (used in) investing activities	4	−190	269	−217	−82
Proceeds from Credit Line	0	0	93	0	0
Payments on Credit Line	0	0	−93	0	0
Payment on convertible notes	0	0	−403	0	0
Proceeds from issuance of common stock	38	15	7	12	7
Employee taxes paid related to net share settlement of equity awards	−4	−3	−2	0	0
Payment of contingent consideration	−24	0	0	−23	0
Net cash provided by (used in) financing activities	9	12	−398	−10	−130
Net change in cash, cash equivalents, and restricted cash	61	−6	−18	−110	−85
Cash paid for income taxes	16	53	37	16	25
Cash paid for interest on debt	0	0	2	3	3

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is SUPERNUS PHARMACEUTICALS, INC.'s CIK number?

SUPERNUS PHARMACEUTICALS, INC.'s SEC CIK number is 0001356576 (1356576). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find SUPERNUS PHARMACEUTICALS, INC.'s SEC filings?

All of SUPERNUS PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did SUPERNUS PHARMACEUTICALS, INC. last report earnings?

SUPERNUS PHARMACEUTICALS, INC. (SUPN) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001356576-26-000020). This is SUPERNUS PHARMACEUTICALS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is SUPERNUS PHARMACEUTICALS, INC.'s most recent earnings 8-K?

SUPERNUS PHARMACEUTICALS, INC.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001356576-26-000020. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View SUPERNUS PHARMACEUTICALS, INC.'s latest earnings 8-K →
Look up any company's CIK number →